Researchers from the Federal Institute of Technology in Lausanne, Switzerland, in collaboration with Flowbone, have developed an innovative injectable hydrogel aimed at treating osteoporosis, a condition affecting one in three women and one in five men over the age of 50.
Osteoporosis occurs when there is an imbalance between bone-resorbing cells and those responsible for bone regeneration. Traditional treatments involve medications that either slow down bone loss or stimulate bone repair, often accompanied by side effects and requiring 6 to 24 months of therapy.
The new hydrogel is composed of hyaluronic acid, a natural component of connective tissues, and hydroxyapatite nanoparticles, the primary mineral found in bone. The gel is injected into weakened areas of bone, promoting active bone growth.
Laboratory studies on rats showed that bone density in treated areas increased by 2 to 3 times within 2 to 4 weeks post-injection. When combined with hormonal treatments and bone-resorption inhibitors, density increased nearly fivefold.
One significant advantage of this hydrogel is its rapid action; it begins working within two weeks as opposed to the year-long timeframe typical of conventional treatments. Additionally, it has fewer side effects and can be used alongside other medications, enhancing overall effectiveness.
Researchers are currently awaiting regulatory approval to conduct clinical trials in humans. If proven effective, this new method could represent a breakthrough in osteoporosis treatment, significantly reducing fracture risk and improving patients' quality of life.